Services
Clinical Trial Bioanalysis
ASI provides high quality clinical trial bioanalysis for pharmaceutical companies, biotechnology organisations, academic partners and Contract Research Organisations.
Our accredited laboratory combines advanced LC-MS/MS and high-resolution mass spectrometry with more than 35 years of scientific expertise to deliver accurate and reliable data for drug development programmes.
We support studies from early phase research through to clinical trials and offer specialist capability in small molecule analysis, pharmacokinetics and complex assay development. All work can be conducted under MHRA Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) compliant conditions.
Select an area below to explore our expertise in more detail.
- Our Bioanalytical Capabilities
- Pharmacokinetic and Metabolite Profiling
- Small Molecule Analysis
- Biomarker and Speciality Assays
- Chiral Separations
- Dry Blood Spot Bioanalysis
Our Bioanalytical Capabilities
ASI offers a comprehensive range of clinical bioanalysis services designed to meet the needs of modern drug development.
Pharmacokinetic and Metabolite Profiling
We provide detailed pharmacokinetic data that supports dose selection, safety evaluation and regulatory submission. Our scientists also perform metabolite identification and analysis to help characterise drug behaviour across different populations.
Small Molecule Analysis
Our team has extensive experience with a wide range of small molecules, including psychedelics, antibiotics, steroids, cardiovascular drugs and treatments for mental health conditions. We specialise in the analysis of complex and unstable compounds.
Biomarker and Speciality Assays
We develop and validate small molecule biomarker assays to support exploratory research and clinical studies. We also provide quantification of compounds such as GLP-1 receptor agonists.
Chiral Separations
For compounds where enantiomeric selectivity is clinically relevant, we offer chiral separation and analysis with high sensitivity and precision.
Dry Blood Spot Bioanalysis
We support studies that require microsampling through validated dry blood spot analysis, enabling minimally invasive collection and simplified logistics.
Speak to Our Experts
Assay Development and Method Validation
We work closely with study teams to design and validate bespoke assays that meet the specific requirements of each trial. Our method development process ensures accuracy, reproducibility and regulatory compliance.
With validated small molecule assays and experience across more than 500 studies, we are well placed to support both standard and highly specialised projects.
State of the Art Technology
ASI invests in advanced instrumentation to deliver the highest analytical performance. Our laboratory features:
UHPLC-MS/MS and UHPLC-HRMS platforms for exceptional sensitivity and specificity
High throughput sample processing through automated liquid handling
A comprehensive LC column library to resolve diverse separation challenges
These technologies enable consistent, high-quality data across large study cohorts and complex analytical workloads.
Therapeutic Areas We Support
Our experience spans a wide range of therapeutic indications, including:
Cardiovascular medicine
Diabetes and metabolic disease
Drug addiction
Hormone replacement therapy
Infectious diseases
Rare diseases
Novel and Emerging Areas of Clinical Development in Psychedelic Treatments
Alcoholism
Treatment resistant depression
Post Traumatic Stress Disorder (PTSD)
Why Choose ASI for Clinical Bioanalysis?
Our goal is to deliver precise analytical results that help study teams progress with confidence, reduce delays and meet regulatory expectations.
More than 35 years of bioanalytical experience
Extensive assay library
Support for more than 500 clinical research studies
Accredited laboratory with ISO/IEC 17025:2017, MHRA GLP and GCP compliance
Expertise in small molecules, biomarkers and emerging treatments
Rapid turnaround and clear communication from an experienced scientific team
Speak to Our Experts
We offer complimentary consultation to help determine the most suitable analytical approach for your study. Whether you require pharmacokinetic data, bespoke assay development or specialist support for a complex compound, our scientific team is here to help.
Contact us to discuss your clinical trial requirements.
What people say about us
“Our pharmacokinetic research collaboration with ASI was seamless from consultation to reporting. The team demonstrated clear expertise, arranged efficient sample logistics and delivered results within our research timeframe.”
“We have worked with ASI for over 20 years. The team is responsive, knowledgeable and reliable, delivering high-quality services at good value.”
“ASI developed and validated our pharmacokinetic assay to a high scientific standard. The work was delivered on time and with clear scientific rigour.”
“We would confidently recommend ASI to others and look forward to future collaborations. Their consistent communication, responsiveness and commitment to quality have been invaluable.”
“ASI supported our large-scale research study with professionalism and flexibility. Their responsiveness during an extended data collection period was particularly valued. We would be pleased to work with them again.”
“Across two clinical trials, ASI delivered accurate and efficient bioanalytical services. Their commitment to quality reporting was evident throughout.”
“It has been a genuine pleasure working with ASI. We would not hesitate to recommend them and hope to collaborate again in future.”
FAQs: All You Need to Know
Can you quantify different types of insulin, such as Humulin, Actrapid, Lantus or Tresiba, for clinical or research studies?
Yes. We provide specialist quantification for human insulin and insulin analogues, including rapid acting and long acting formulations, as part of clinical, research or exploratory bioanalysis.
Do you offer bioanalysis for insulin analogues like Humalog, NovoRapid or Apidra during pharmacokinetic studies?
Yes. Our LC-MS/MS methods can support PK and exploratory studies involving fast acting insulin analogues where measurement of concentration, exposure or stability is required.
Can ASI develop or validate assays for GLP-1 agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound)?
We offer assay development and validation for a range of emerging therapeutic compounds, including GLP-1 receptor agonists and dual agonists, depending on study requirements.
Do you provide C-peptide analysis alongside insulin measurement in clinical studies?
Yes. C-peptide analysis can be included to support studies that require differentiation between endogenous insulin and administered insulin or insulin analogues.
Can you support pharmacokinetic profiling for semaglutide or tirzepatide in early phase studies?
We can support PK and exploratory work for these compounds through validated LC-MS/MS methods or bespoke assay development, depending on the study design.
Get in Touch
We welcome enquiries from new and existing clients. Whether you require toxicology support, clinical bioanalysis, therapeutic drug monitoring or expert interpretation, our team is here to help.
General Enquiries & Helpline
info@bioanalytics.co.uk
+44 (0)20 8725 2405